hit counter
Achieve Life Sciences, Inc. (ACHV) Stock News Sentiment & Price - Sentifly
ACHV - Sentifly


Profile

Watchlist

Your watchlist is empty. Go add some tickers to it!



Achieve Life Sciences, Inc. (ACHV)

USA
Biotechnology
NASDAQ
ACHV Price and Sentiment
1MO
1D
Positive, Negative
Loading chart...
ACHV Latest news
Seeking Alpha
Neutral
Achieve Life Sciences, Inc. (ACHV) CEO John Bencich on Q3 2021 Results - Earnings Call Transcript
2021-11-09 19:48

Achieve Life Sciences, Inc. (ACHV) CEO John Bencich on Q3 2021 Results - Earnings Call Transcript

GlobeNewsWire
Neutral
Achieve Reports Financial Results for Third Quarter 2021 and Provides Update on Cytisinicline Development
2021-11-09 16:05

SEATTLE, Wash and VANCOUVER, British Columbia, Nov. 09, 2021 (GLOBE NEWSWIRE) -- -- Achieve Life Sciences, Inc. (Nasdaq: ACHV), a clinical-stage pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation and nicotine addiction, today announced third quarter 2021 financial results and provided an update on the cytisinicline clinical development program.

GlobeNewsWire
Neutral
Achieve Life Sciences Announces Participation in November Investor Conferences
2021-11-04 08:30

SEATTLE, Wash and VANCOUVER, British Columbia, Nov. 04, 2021 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (Nasdaq: ACHV), a clinical-stage pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation and nicotine addiction, today announced that its management team will hold one-on-one investor meetings at the Alliance Global Partners' (A.G.P.) Biotech & Specialty Pharma Conference and the Torrey Hills Capital Emerging Growth Conference during November 2021. Details are as follows:

Benzinga
Positive
Achieve Life Sciences To Start Cytisinicline's Trial For Nicotine E-cigarette Cessation
2021-11-02 13:03

The FDA has signed off Achieve Life Sciences Inc's (NASDAQ: ACHV) Investigational New Drug (IND) application to investigate cytisinicline as a cessation treatment for nicotine e-cigarette users. In addition to the ongoing Phase 3 program for cytisinicline treatment in combustible cigarette cessation, the Company expects to initiate the ORCA-V1 e-cigarette and vape cessation trial in Q2 of 2022.

GlobeNewsWire
Neutral
Achieve Life Sciences to Announce Third Quarter 2021 Financial Results and Host Conference Call and Webcast on November 9, 2021
2021-10-26 08:30

Seattle, WA/ Vancouver, BC , Oct. 26, 2021 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (Nasdaq: ACHV), a clinical-stage pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation and nicotine addiction, today announced that it will report its third-quarter 2021 financial results and provide an update on the cytisinicline development program on Tuesday, November 9, 2021, at 4:30 PM EST.

Accesswire
Neutral
Achieve Life Sciences to Participate in Upcoming Investor Conferences
2021-09-15 05:30

SEATTLE, WA and VANCOUVER, BC / ACCESSWIRE / September 15, 2021 / Achieve Life Sciences, Inc. (NASDAQ:ACHV), a clinical-stage pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation and nicotine addiction, today announced that John Bencich, Chief Executive Officer, will participate in two upcoming investor conferences. Mr. Bencich will present at the virtual Oppenheimer Fall Healthcare Life Sciences & MedTech Summit on Tuesday, September 21st at 3:45PM ET.

Accesswire
Neutral
Achieve Life Sciences Announces Presentation of Cytisinicline Data at the 21st Annual Society for Research on Nicotine & Tobacco (SRNT-E) Virtual Conference
2021-09-14 05:30

SEATTLE, WA & VANCOUVER, BC / ACCESSWIRE / September 14, 2021 / Achieve Life Sciences, Inc. (NASDAQ:ACHV), a clinical-stage pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation and nicotine addiction, announced that cytisinicline data will be presented at two sessions during the upcoming Society for Research on Nicotine & Tobacco (SRNT-E) Conference to be held virtually September 15-17, 2021. Presentation Details "Cytisinicline may benefit smokers who previously failed to quit smoking with varenicline: A subgroup analysis of the ORCA-1 trial" A subgroup analysis from the ORCA-1 Phase 2 study of smokers who had previously failed Chantix® (varenicline) demonstrated a Week 4 abstinence rate of 51.3% upon treatment with cytisinicline using the three times daily (TID) regimen, compared with 15.8% with placebo (p= 0.009).

Accesswire
Neutral
Achieve Life Sciences Announces Expansion of Cytisinicline Clinical Operations Team and Granting of Inducement Awards
2021-08-13 05:30

SEATTLE, WA and VANCOUVER, BC / ACCESSWIRE / August 13, 2021 / Achieve Life Sciences, Inc. (NASDAQ:ACHV), a clinical-stage pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation and nicotine addiction, today announced that the Company has expanded its Clinical Operations Team with the hiring of a Director of Clinical Operations, a Senior Manager of Clinical Trials, and a Senior Director of Biometrics. "We are excited to welcome our new clinical team members to Achieve and look forward to their contributions to the cytisinicline development program, including their efforts to support our fully enrolled Phase 3 ORCA-2 trial in combustible cigarette cessation and the planned Phase 2 ORCA-V1 trial in nicotine e-cigarette cessation," commented Dr. Cindy Jacobs, Achieve's President and Chief Medical Officer.

Seeking Alpha
Neutral
Achieve Life Sciences, Inc. (ACHV) CEO John Bencich on Q2 2021 Results - Earnings Call Transcript
2021-08-13 03:57

Achieve Life Sciences, Inc. (ACHV) CEO John Bencich on Q2 2021 Results - Earnings Call Transcript

Accesswire
Neutral
Achieve Reports Financial Results for Second Quarter 2021 and Provides Corporate Update
2021-08-11 16:05

SEATTLE, WA and VANCOUVER, BC / ACCESSWIRE / August 12, 2021 / Achieve Life Sciences, Inc. (Nasdaq:ACHV), a clinical-stage pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation and nicotine addiction, today announced second quarter 2021 financial results and provided an update on the cytisinicline clinical development program. Recent Events & Highlights Announced completion of enrollment in the Phase 3 ORCA-2 clinical trial evaluating the efficacy and safety of 3.0 mg cytisinicline dosed 3 times daily (TID) compared to placebo in adult smokers Awarded grant from the National Institute on Drug Abuse (NIDA) of the National Institutes of Health (NIH) for the evaluation of cytisinicline in cessation of nicotine e-cigarette use Issued two new patents from the United States Patent and Trademark Office covering the novel 3.0 mg TID cytisinicline dosing regimen Closed financing with gross proceeds of $23 million, prior to deducting underwriting discoun

Loading more news...